The Trump administration has finalized a deal with drugmaker AbbVie to cut the cost of certain medicines, marking the latest pact as part of its “Most Favored Nation” pricing initiative.

AbbVie commits to lowering Medicaid drug prices and investing $100 billion in US R&D and capital investments over the next decade. The TrumpRx program will expand direct-to-patient offerings, ...

Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...

AbbVie has also pledged to participate in TrumpRx and offer many of its products, including Humira, on a direct-to-patient ...

AbbVie’s popular arthritis drug Humira is a powerhouse, producing $14 billion in annual sales to make up 60 percent of the drugmaker’s revenue. However, generic versions of the drug are around the ...

The Food and Drug Administration has designated Celltrion’s Yuflyma (adalimumab-aaty), as an interchangeable biosimilar to Abbvie's Humira (adalimumab). Yuflyma is a high-concentration (100mg/ml) and ...

Medicare Part D may cover Humira when a person can self-administer it at home. A person’s Part D costs for Humira will depend on the plan’s formulary and their specific plan. Similarly, Medicare ...